Starpharma to advance with phase III studies for VivaGel
- 11 January, 2012 11:37
- Comments
Starpharma has kicked off the year with a tick from the US Food and Drug Administration for its study design for phase III trials of VivaGel under the FDA’s Special Protocol Assessment scheme.
The agreement with the FDA confirms that the study design, endpoints, statistical analyses and other aspects of the trial are acceptable for achieving regulatory approval.
The company intends to undertake two phase III trials of VivaGen for the treatment of bacterial vaginosis (BV) this year, with results anticipated before the year’s end.
Assuming positive results, the company intends to partner in order to progress to marketing stage.
“Following our recent financing, we are also implementing various initiatives in collaboration with our CRO to expedite the trial timelines as much as possible,” said Dr Jackie Fairley, Chief Executive Officer of Starpharma.
Starpharma’s (ASX:SPL) is steady at $1.20.
-
UniQuest brokers international biofuel partnership
-
Apollo develops needle-free topical vaccine
-
Study reveals link between tea and rheumatoid arthritis
-
Halcygen (ASX:HGN) to expand board following departure of director and COO
-
AstraZeneca invests in Victoria's NeuProtect
-
Molecular & Cell Biology for Dummies
-
Molecular Forensics
-
Dictionary of DNA and Genome Technology 2E
-
An Introduction to Molecular Biotechnology - Molecular Fundamentals, Methods and Applications in Modern Biotechnology
-
Writing Scientific Research Articles - Strategy and Steps
-
Proteins - Structure and Function
-
Introduction to Statistics for Forensic Scientists
-
Fluorescence Applications in Biotechnology and Life Sciences
-
Statistics for Terrified Biologists
Get exclusive access to ALS, invitation only events, reports & analysis. 
Comments
Post new comment